In-vitro selection of HIV-1 variants resistant to non-nucleoside reverse transcriptase inhibitors in monocyte-derived macrophages

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 6, 1997, Pages 847-853

  Been Tiktak, A M M ^a,b   De Haas, C J C ^a   De Graaf, L ^a   Boucher, C A B ^a   Verhoef, J ^a   Borleffs, J C C ^b   Nottet, H S L M ^a   Schuurman, R ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ATEVIRDINE; ATEVIRDINE MESYLATE; DELAVIRDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CROSS RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; VIRUS INHIBITION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; DELAVIRDINE; DRUG RESISTANCE, MICROBIAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MACROPHAGES; MOLECULAR SEQUENCE DATA; MONOCYTES; PIPERAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE HOMOLOGY, AMINO ACID; ZIDOVUDINE;

EID: 0031450845     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.6.847     Document Type: Article

References (24)

1. Rich, E. A., Chen, I. S., Zack, J. A., Leonard, M. L. & O'Brien, W. A. (1992). Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1). Journal of Clinical Investigation 89, 176-83.
2. Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A. & Chen, I. S. Y. (1990). HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213-22.
3. Bukrinsky, M. I., Stanwick, T. L., Dempsey, M. P. & Stevenson, M. (1991). Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 254, 423-7.
4. Gendelman, H. E., Orenstein, J. M., Baca, L. M., Weiser, B., Burger, H., Kalter, D. C. et al. (1989). The macrophage in the persistence and pathogenesis of HIV infection. AIDS 3, 475-95.
5. Sato, H., Orenstein, J., Dimitrov, D. & Martin, M. (1992). Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. Virology 186, 712-24.
6. Nottet, H. S. L. M., Persidsky, Y., Sasseville, V. G., Nukuna, A. N., Bock, P., Zhai, Q. et al. (1996). Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. Journal of Immunology 156, 1284-95.
7. Price, R. W., Brew, B., Sidtis, J., Rosenblum, M., Scheck, A. C. & Cleary, P. (1988). The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 239, 586-92.
8. Nottet, H. S. L. M. & Gendelman, H. E. (1995). Unraveling the neuroimmune mechanisms for the HIV-1 associated cognitive/ motor complex. Immunology Today 16, 441-8.
9. Perno, C. F., Yarchoan, R., Cooney, D. A., Hartman, N. R., Gartner, S., Popovic, M. et al. (1988). Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. Journal of Experimental Medicine 168, 1111-25.
10. Perno, C. F., Cooney, D. A., Gao, W. Y., Hao, Z., Johns, D. G., Foli, A. et al. (1992). Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood 80, 995-1003.
11. Nunberg, J. H., Schleif, W. A., Boots, E. J., O'Brien, J. A., Quintero, J. C., Hoffman, J. M. et al. (1991). Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. Journal of Virology 65, 4887-92.
12. Portegies, P., Enting, R. H., de Jong, M. D., Danner, S. A., Reiss, P., Goudsmit, J. et al. (1994). AIDS dementia complex and didanosine. Lancet 344, 759.
13. Balis, F. M., Pizzo, P. A., Butler, K. M., Hawkins, M. E., Brouwers, P., Husson, R. N. et al. (1992). Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. Journal of Infectious Diseases 165, 99-104.
14. Nottet, H. S. L. M., van Asbeck, B. S., de Graaf, L., de Vos, N. M., Visser, M. R. & Verhoef, J. (1994). Role for oxygen radicals in self-sustained HIV-1 replication in monocyte-derived macrophages: enhanced HIV-1 replication by N-acetyl-L-cysteine. Journal of Leukocyte Biology 56, 702-7.
15. Nottet, H. S. L. M., Oteman, M. H., Visser, M. R. & Verhoef, J. (1994). Anti-human immunodeficiency virus type 1 activities of novel non-nucleoside reverse transcriptase inhibitors. Journal of Antimicrobial Chemotherapy 33, 366-8.
16. Japour, A. J., Mayers, D. L., Johnson, V. A., Kuritzkes, D. R., Beckett, L. A., Arduino, J. M. et al. (1993). Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrobial Agents and Chemotherapy 37, 1095-101.
17. 50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics. In A Computer Software for IBM-PC and Manual, pp. 19-32. Elsevier-Biosoft, Cambridge, UK.
18. Boucher, C. A. B., Keulen, W., van Bommel, T., Nijhuis, M., de Jong, D., de Jong, M. D. et al. (1996). Human immunodeficiency virus type 1 drug susceptibility determination using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrobial Agents and Chemotherapy 40, 2404-9.
19. Ratner, L., Haseltine, W., Patarca, R., Livak, K. J., Starcich, B., Josephs, S. F. et al. (1985). Complete nucleotide sequence of the AIDS virus HTLV-III. Nature 313, 277-84.
20. Khlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A. & Steitz, T. A. (1992). Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-90.
21. Larder, B. A. (1992). 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy 36, 2664-9.
22. Balzarini, J., Karlsson, A., Perez Perez, M. J., Camarasa, M. J., Tarpley, W. G. & De Clercq, E. (1993). Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. Journal of Virology 67, 5353-9.
23. Richman, D. D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S. A. et al. (1994). Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Journal of Virology 68, 1660-6.
24. Dueweke, T. J., Pushkarskaya, T., Poppe, S. M., Swaney, S. M., Zhao, J. Q., Chen, I. S. et al. (1993). A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proceedings of the National Academy of Sciences of the USA 90, 4713-7.